Analysts update price targets of NuVasive stock — 3 quick points

Written by Megan Wood | August 19, 2016 | Print  |

Analysts have updated their price targets for NuVasive shares, according to Fiscal Standard.

Here are three quick points:

 

1. Jeffries analysts reiterated their "buy" rating for NuVasive stock with a price target of $72, on July 27.

 

2. Barclays analysts reiterated their "overweight" rating for NuVasive shares with a price target of $71, on July 27.

 

3. On July 27, Brean Capital analysts reiterated their "buy" rating for NuVasive stock with a price target of $70.

 

More articles on devices:
DePuy Synthes, Acumed, Stryker market leaders in Japan device market: 5 takeaways
Medical device makers pivot towards value-based care: 7 thoughts
Orthogrid Systems offering outpatient and short-stay total joint surgeons complete control: 4 thoughts

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months